Voloridge Investment Management
PTGX icon

Voloridge Investment Management’s Protagonist Therapeutics PTGX Stock Holding History

Voloridge Investment Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-15,588
Closed -$431K – 1564
2023
Q2 		$431K Sell
15,588
-449,735
-97% -$11.3M ﹤0.01% 1252
2023
Q1 		$10.7M Buy
465,323
+297,954
+178% +$5M 0.05% 437
2022
Q4 		$1.83M Sell
167,369
-259,024
-61% -$2.19M 0.01% 986
2022
Q3 		$3.59M Sell
426,393
-170,094
-29% -$1.61M 0.02% 768
2022
Q2 		$4.72M Buy
596,487
+519,886
+679% +$6.29M 0.02% 701
2022
Q1 		$1.81M Sell
76,601
-107,047
-58% -$3.02M 0.01% 988
2021
Q4 		$6.28M Sell
183,648
-366,435
-67% -$11.6M 0.03% 631
2021
Q3 		$9.75M Buy
550,083
+543,579
+8,358% +$23.2M 0.06% 441
2021
Q2 		$292K Buy
+6,504
New +$215K ﹤0.01% 1522

Other funds holding PTGX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Voloridge Investment Management's PTGX Position: Q3 2023 in Review

Voloridge Investment Management sold out of Protagonist Therapeutics (PTGX) in Q3 2023, closing a stake of 15,588 shares — an estimated $431K sold.

Voloridge Investment Management first reported a position in PTGX in Q2 2021 and held it in 9 quarters. The position peaked at $10.7M in Q1 2023. 144 funds tracked by Wall St. Rank hold PTGX as of Q3 2023.

  • Voloridge Investment Management reported no remaining Protagonist Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Voloridge Investment Management sold 15,588 Protagonist Therapeutics shares in Q3 2023, an estimated $431K.
  • Voloridge Investment Management first reported a position in Protagonist Therapeutics in Q2 2021 and held it in 9 quarters.
  • Voloridge Investment Management's Protagonist Therapeutics position peaked at $10.7M in Q1 2023.
  • 144 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2023.

Based on Voloridge Investment Management's 13F filing for Q3 2023, filed 14 Nov 2023.